Similarly, the encephalopathy, specifically the PRES experienced by the other patient, is another rare AE for PD-1/PD-L1 therapies39 and checkpoint inhibitors in general40. This evidence concerns the gene PDCD1 and Posterior Leukoencephalopathy Syndrome.